Question explored with the scientific record
Conversation so far
- 1 Jaudiance and heart function
- 2 Does it help improve cardiac output after stent surgery
Answered on this page ↓
Does it help improve cardiac output after stent surgery
Stenting fixes a blocked artery. Empagliflozin does not raise cardiac output in a normal heart, and no trial here tested it after stenting.
Cardiac output is how much blood the heart pumps per minute. None of these records measured it after stent surgery. The closest evidence is in mice with pressure-overload heart failure, where empagliflozin preserved systolic function and improved mitochondrial energy use [1][3]. That is a mouse model, not a person after a stent.
The one human study that touches this exact setting is a warning, not a benefit. A 77-year-old on empagliflozin developed euglycemic ketoacidosis after a stent procedure, even after the drug was stopped [2]. That is a rare but real risk in the post-stent window.
| Setting | What was measured | Result |
|---|---|---|
| Mice, pressure overload | Ejection fraction | Decline blunted [3] |
| Humans, HFrEF | CV death or HF hospitalization | 19.4% vs 24.7% [4] |
| Humans, post-stent | Ketoacidosis | One case report [2] |
The hard-outcome trials that do exist are about heart failure, not post-stent cardiac output [4][5]. They show fewer hospitalizations, not more pumping power.
My call: there is no evidence empagliflozin improves cardiac output after stent surgery, and the post-stent ketoacidosis risk is real. Confidence: low, because the right study was not done.
Sources used 5
-
Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
In nondiabetic mice with established pressure-overload heart failure, empagliflozin treatment prevented the progressive decline in systolic function and preserved ex vivo cardiac function without altering cardiac remodeling or diastolic function.
DOI: 10.1016/j.jacbts.2017.07.003 -
Euglycemic Diabetic Ketoacidosis in a Patient with Type 2 Diabetes and Preserved Insulin Secretion on Empagliflozin
This case report describes a 77-year-old male with type 2 diabetes who developed euglycemic diabetic ketoacidosis after percutaneous coronary intervention, despite preserved insulin secretion and cessation of SGLT2 inhibitor therapy.
DOI: 10.2169/internalmedicine.4752-24 -
Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
In a non-diabetic mouse model of pressure overload-induced heart failure, four weeks of empagliflozin improved mitochondrial function and reduced oxidative stress through direct cardiac effects, attenuating remodeling and improving cardiac function without changing blood glucose…
DOI: 10.3389/fcvm.2022.859253 -
P003. An Evidence Based Quality Improvement Project of the Impact of a Nurse Practitioner Led Heart Failure, Self-Care Focused, Patient Education on Healthcare Related Quality of Life
This study investigates the effects of empagliflozin on cardiovascular and renal outcomes in patients with heart failure, demonstrating a significant reduction in the risk of cardiovascular death and hospitalization for heart failure compared to placebo.
DOI: 10.1016/j.hrtlng.2021.03.058 -
Sodium-Glukose-Transporter 2(SGLT2)-Hemmer bei Herzinsuffizienz
ESC 2021 guidelines endorse SGLT2 inhibitors as first-line therapy for heart failure with reduced ejection fraction, summarizing DAPA-HF and EMPEROR-Reduced which show around a 5% absolute reduction in the primary endpoint (HF hospitalization or cardiovascular death) with benefi…
DOI: 10.1007/s12181-021-00524-2